Hinge Bio Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
20
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$30.6M
- Investors
-
9
Hinge Bio General Information
Description
Operator of a biotech company intended to work for the development of a new class of flexible, extendible, and cooperatively binding therapeutics and diagnostics. The company focuses on facilitating therapeutics capable of simultaneously binding either a disease target with multiple hands and targeting different oncology, metabolic disease, and neurodegenerative disorders, enabling medical providers to diagnose diseases at an early stage and provide proper treatment.
Contact Information
Website
www.hingebio.comCorporate Office
- 900 Island Drive
- Suite 102
- Redwood City, CA 94065
- United States
Corporate Office
- 900 Island Drive
- Suite 102
- Redwood City, CA 94065
- United States
Hinge Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC (Series A) | 15-Jan-2025 | $30.6M | Completed | Generating Revenue | ||
| 6. Later Stage VC | 01-Feb-2021 | Completed | Startup | |||
| 5. Later Stage VC (Series A) | 27-Feb-2020 | Completed | Startup | |||
| 4. Grant | 01-Jan-2018 | Completed | Startup | |||
| 3. Grant | 31-Dec-2017 | Completed | Startup | |||
| 2. Accelerator/Incubator | 18-Apr-2017 | Completed | Startup | |||
| 1. Grant | 01-Jan-2017 | $225K | Completed | Startup |
Hinge Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A' | ||||||||
| Series A |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Hinge Bio Patents
Hinge Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026107318-A1 | A cd19/cd20 bispecific antibody with dual fc domains | Pending | 15-Nov-2024 | ||
| WO-2026107307-A1 | Tetrahedral constructs binding folate and cd3 | Pending | 15-Nov-2024 |
Hinge Bio Signals
Hinge Bio Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| InVivium Capital | Venture Capital | Minority | ||
| Lightswitch Capital | PE/Buyout | Minority | ||
| Point72 Asset Management | Hedge Fund | Minority | ||
| Ridgeback Capital | Venture Capital | Minority | ||
| Thornapple River Capital | Venture Capital | Minority |
Hinge Bio FAQs
-
When was Hinge Bio founded?
Hinge Bio was founded in 2015.
-
Where is Hinge Bio headquartered?
Hinge Bio is headquartered in Redwood City, CA.
-
What is the size of Hinge Bio?
Hinge Bio has 20 total employees.
-
What industry is Hinge Bio in?
Hinge Bio’s primary industry is Drug Discovery.
-
Is Hinge Bio a private or public company?
Hinge Bio is a Private company.
-
What is the current valuation of Hinge Bio?
The current valuation of Hinge Bio is .
-
What is Hinge Bio’s current revenue?
The current revenue for Hinge Bio is .
-
How much funding has Hinge Bio raised over time?
Hinge Bio has raised $66.8M.
-
Who are Hinge Bio’s investors?
InVivium Capital, Lightswitch Capital, Point72 Asset Management, Ridgeback Capital, and Thornapple River Capital are 5 of 9 investors who have invested in Hinge Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process